3M littmann stethoscopes and eko collaborate to improve healthcare outcomes in patients

WORLD – 3M Littmann Stethoscopes, that deals in the production of medical devices and Eko digital innovations, a company specializing in artificial intelligence (AI), collaborate to deliver comprehensive healthcare solutions that will drive better patient outcomes. This is a collaboration that will see both companies try to meet the growing demand on auscultation in healthcare and the advancing digital technology by marrying 3M Littmann stethoscope technology with advanced Eko digital innovations. The collaboration has led to the development of an innovation, 3M Littmann Core digital stethoscope that offers clinicians access…

Read More

A Tata memorial centre led study concludes that 50% oral cancer patients die within a year of diagnosis

INDIA – The first-of-its-kind study on the ‘cost of illness analysis of oral cancer’, conducted by Tata Memorial Centre in Mumbai, reveals that half of oral cancer patients in India die within a year of diagnosis and are aged between 30-50 years. The study was conducted on 100 consecutive oral cancer patients who sought treatment at the facility between October 2019 and March 2020 and pointed out that most of the patients who receive some form of treatment are left unemployed hence they become an economic burden to their families.…

Read More

Max Healthcare collaborates with digital health solutions to launch a remote healthcare monitoring system

INDIA – Max Healthcare, a giant Indian based corporation in the healthcare sector, has launched an artificial intelligence (AI) powered device integrated patient monitoring framework, claimed to be the first in the country. The project was a success owing to the fact that Max Healthcare collaborated with digital health solutions, an Indian social business that uses technology and creativity to make high-quality health services. This was a move Max Healthcare undertook in a bid to expand its geography of care, allowing patients from across India and globally to stay connected…

Read More

University of Oxford is currently studying ivermectin as a possible therapy against COVID-19 in the UK

UK – Researchers from the university of Oxford under the PRINCIPLE study project are currently giving Ivermectin, a widely used anti-parasitic drug, to over-50s with COVID symptoms to see if it can keep them out of hospital. PRINCIPLE is a nationwide clinical study from the University of Oxford in collaboration with the British government trying to find COVID-19 treatments for recovery at home. The project is currently having any willing citizen over-50s with an underlying health condition or experiencing breathlessness and have had COVID symptoms for up to 14 days…

Read More

Cuba inches closer to rolling out its vaccines soberana and Abdala

CUBA – The Caribbean island nation of 11 million people, which has been under a strict United States (US) trade embargo for decades, is in process of developing five experimental shots, including Soberana 02 and Abdala, which reached final-stage trials last month. With both Soberana and Abdala in stage-three clinical trials, Cuba is racing towards potentially becoming the first country in Latin America to develop its own shot against the coronavirus. The names of the vaccines reveal much about how Cuba sees its national effort, Soberana translates as “sovereign”, while…

Read More

BioNTech’s BNT111 phase 2 clinical trial makes progress as patient with advanced Melanoma treated

GERMANY – BioNTech, a German pharmaceutical company, has announced that the first patient has been treated in its BNT111 phase 2 cancer medication trial. Currently, the study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control or can be refereed to hyperpigmentation. BNT111…

Read More

Pfizer’s tofacitinib gains usage traction based on data from Brazilian hospitalized patients

USA – Pfizer Inc. and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced that the findings from the STOP-COVID study came out positive. The New England Journal of Medicine published positive findings from the study evaluating the efficacy and safety of oral Janus kinase (JAK) inhibitor tofacitinib in 289 hospitalized adult patients with COVID-19 pneumonia who were not on ventilation. Tofacitinib is a type of drug known as a Janus kinase (JAK) inhibitor that works by blocking the action of Janus kinase enzymes, which are involved…

Read More

Sun Pharma announces settlement of patent litigation with Celgene in US

USA – Sun Pharmaceutical Industries today announced settlement of patent litigation for generic Revlimid (lenalidomide) in the US. Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS), cancer forms that fall under leukemia. Multiple myeloma is a relatively uncommon cancer. In the United States, the lifetime risk of getting multiple myeloma is 1 in 132 (0.76%). The American Cancer Society’s estimates for multiple myeloma in the United States for 2021 are, About 34,920 new cases will be…

Read More

COVID-19 crisis in Indonesia worsens as the country reports a 2m milestone of reported cases

INDONESIA – The Southeast Asian nation Indonesia, hit the 2 million mark as its hospital occupancy rates soars to over 75percent in Jakarta and other hard-hit areas with increased COVID-19 related deaths being reported. Official figures as of Monday showed Indonesia had recorded a daily record high of 14,536 cases, taking the total to just over two million with nearly 55,000 deaths, among a population of nearly 270 million. The infamous milestone comes after the daily recorded rate double in recent weeks with the country’s authority identifying the presence of…

Read More

Boehringer Ingelheim’s Pradaxa approved by the FDA for oral pediatric use

USA – The Food and Drug Administration (FDA) has approved Boehringer Ingelheim’s Pradaxa as the first oral blood thinning medication suitable for children 12 years and below in the USA. The medication Pradaxa will be available for use for children with venous thromboembolism immediately after treatment with a blood thinner given by injection for at least five days. Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis and pulmonary embolism with deep vein thrombosis (DVT) occurring when a blood clot forms in a deep vein, usually in the…

Read More